Association of bcl-2, bax, bcl-xL and interleukin-l β-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia

Leukemia

Volumn 10, Issue SUPPL. 3, 1996, Pages

  Stoetzer, O J ^a,b   Nussler V ^a,b   Darsow, M ^a   Gullis, E ^a   Pelka Fleischer, R ^b   Scheel, U ^a   Wilmanns, W ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

AML; Bax; Bcl 2; Bcl xL; Drug resistance; ICE

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; INTERLEUKIN 1BETA CONVERTING ENZYME; MITOXANTRONE; PROTEIN BCL 2; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AMINO ACID SEQUENCE; APOPTOSIS; BLAST CELL; BONE MARROW; BONE MARROW BIOPSY; CELL DEATH; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0029846602     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Nakano H, Shinohara K. X-ray induced cell death: apoptosis and necrosis. Radiation Res 1994; 140: 1-9.
2. Kaufman SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 1989; 49: 5870-5877.
3. Kamesaki S, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 1993; 53: 4251-4256.
4. Dubrez L, Goldwasser F, Genne P, Pommier Y, Solary E. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 1995; 9: 1013-1024.
5. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985; 82: 7439-7443.
6. Krajewski S, Tanaka S, Takayana S, Schibler MJ, Fenton W, Reed JC. Investigations of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, an outer mitochondrial membranes. Cancer Res 1993; 53: 4701-4714.
7. Reed JC, Miyashita T, Cuddy M, Cho D. Regulation of p26-Bcl-2 protein levels in human peripheral blood lymphocytes. Am J Pathol 1992; 67: 443-449.
8. Delia D, Arello A, Soligo D, Fontanella E, Melani C, Pezzalla F, Pierotti M, Della Porta G. Bcl-2-proto-oncogene expression in normal and neoplastic human myeloid cells. Blood 1992; 79: 1291-1298.
9. Hsu B, Marin MC, Krisbay S, McConnel K, McDonnell TJ. Expression of bcl-2 confers multidrug resistance to chemotherapy induced cell death. Cancer Bull 1994; 46: 125-129.
10. Hockenbery D, Numez G, Milliman C. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
11. Reed J. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1-6.
12. Oltavi ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993; 74: 609-619.
13. Williams GT, Smith C. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993; 74: 777-779.
14. Krajewski S, Krajewski M, Shabaik A, Miyashita T, Wang HG. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994; 145: 1323-1326.
15. Boise LH, Gonzalez-Garcia M, Postena CE, Ding L, Lindstren T, Turka LA, Mao X, Nunez G, Thompson CB. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74: 597-608.
16. Nunez G, Merino G, Grillot D, Gonzalez-Garcia M. Bcl-2 and Bcl-x: regulatory switches for lymphoid death and survival. Immunol Today 1994; 15: 582-588.
17. Takayama S, Sato T, Krajewski S, Kochel K, Irie S, Milian JA. Cloning and functional analysis of BAG-1 : a novel Bcl-2-binding protein with anti-cell death activity. Cell 1995; 80: 279-284.
18. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for bcl-xL and bcl-2, displaces bax and promotes cell death. Cell 1995; 80: 285-291.
19. Rehnolds JE, Yang T, Quian L, Jenkinson JD, Zhou P, Eastman A, Graig RW. Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res 1994; 54: 6348-6352.
20. Yang T, Kozopas KM, Graig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap, but are not identical to, those of Bcl-2. J Cell Biol 1995; 128; 1173-1184.
21. Yuan J, Shakam S, Ledoux S, Ellis HM, Horvitz HR. The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme. Cell 1993; 75: 641-652.
22. Miura M, Zhu H, Rotello R, Hertwieg EA, Yuan J. Induction of apoptosis in fibroblasts by IL-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell 1993; 75: 653-655.
23. Campos L, Rouault JP, Sabido O. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993; 81: 3091-3096.
24. Maung ZT, MacLean FR, Reid MM, Pearson ADJ, Proctor SJ, Hamilton PJ, Hall AG. The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol 1994; 88; 105-109.
25. Mezger J, Permanetter W, Gerbel AL, Wilmanns W, Lamerz R. Tumour associated antigens in diagnosis of serous effusions. J Clin Pathol 1988; 41: 633-643.
26. Nuessler V, Pelka-Fleischer R, Zwierzina H, Nerl C, Beckert B, Gullis E, Gieseler F, Bock S, Bartl R, Petrides PE, Wilmanns W. Clinical importance of P-glycoprotein-related resistance in leukemia and myelodysplastic syndrome - first experience with their reversal. Ann Hematol 1994; 69: 25-29.
27. Lepelley P, Soenen V, Preudhomme C, Merlat A, Crosson A. Bcl-2 expression in myelodysplastic syndromes and its correlation with hematological features, p53 mutations and prognosis. Leukemia 1995; 9: 726-730.
28. Hu ZB, Yang GS, Li M, Miyamoto N, Minder MD, McCullock EA. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals. Leukemia 1995; 9: 989-998.
29. Shimizu S, Eguchi Y, Kosaka H, Kamiike W, Matsuda H, Tsugimoto Y. Prevention of hypoxia-induced cell death by bcl-2 and bcl-xL. Nature 1995; 374: 811-813.
30. Schlaifer D, Marck M, Krajewski S, Laurent G, Pris J, Delsol G, Reed JC. High expression of the bcl-x gene in Reed-Sternberg cells of Hodgkin's disease. Blood 1995; 85: 2671-2674.
31. Schwarze MM, Hawley RG. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL. Cancer Res 1995; 55: 2262-2265.
32. Fernandes-Alnemri T, Litwach G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 1994; 269: 30761-30764.
33. Lavabre-Bertrand T, Duperray C, Brinet C, Poncelet P, Extrayat C, Bourquard P, Lavabre-Bertrand C, Brockner J, Navarro M, Janossy G. Quantification of CD24 and CD45 antigens in parallel allows a precise determination of B-cell maturation stages: relevance for the study of B-cell neoplasias. Leukemia 1994; 8: 402-408.